We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Eli Lilly and (LLY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of LLY and the rest of the Medical group's stocks.
Eli Lilly and is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for LLY's full-year earnings has moved 2.06% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that LLY has returned about 35.99% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.51% on a year-to-date basis. As we can see, Eli Lilly and is performing better than its sector in the calendar year.
To break things down more, LLY belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #66 in the Zacks Industry Rank. This group has gained an average of 12.06% so far this year, so LLY is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to LLY as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Eli Lilly and (LLY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of LLY and the rest of the Medical group's stocks.
Eli Lilly and is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for LLY's full-year earnings has moved 2.06% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that LLY has returned about 35.99% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.51% on a year-to-date basis. As we can see, Eli Lilly and is performing better than its sector in the calendar year.
To break things down more, LLY belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #66 in the Zacks Industry Rank. This group has gained an average of 12.06% so far this year, so LLY is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to LLY as it looks to continue its solid performance.